BRIEF-Valeant and Progenics announce FDA approvals for relistor

Tue Jul 19, 2016 6:18pm EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 19 (Reuters) - Progenics Pharmaceuticals Inc :

* Valeant expects to commence sales of relistor tablets in U.S. in Q3 of 2016

* Valeant and Progenics announce FDA approves relistor tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain

* FDA has approved relistor (methylnaltrexone bromide) tablets for treatment of opioid-induced constipation Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)